Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

Lori Muffly; Noelle V. Frey; Gregory W. Roloff; Jae A. Park; Bhagirathbhai Dholaria; Anjali Advani; Veronika Bachanova; Ryan D. Cassaday; Michael Daunov; Kaitlyn C. Dykes; Vivian Irizarry Gatell; Michael R. Grunwald; Talal Hilal; La Quisa C. Hill; Omer Jamy; Vamsi K. Kota; Muthu Veera Kumaran; Chenyu Lin; Aaron C. Logan; Marlise R. Luskin; Kristen M. O'Dwyer; Caspian Oliai; Olalekan O. Oluwole; Joshua P. Sasine; Marc S. Schwartz; Melhem M. Solh; Wendy Stock; Stephanie B. Tsai; Mattew Ulrickson; Sumithira Vasu; Eunice S. Wang; Fevzi Firat Yalniz; Stephen A. Strickland; Jessica T. Leonard; Bijal D. Shah; Ibrahim Aldoss

doi:10.1182/blood.2026033559

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

Lori Muffly
, Noelle V. Frey
, Gregory W. Roloff
, Jae A. Park
, Bhagirathbhai Dholaria
, Anjali Advani
, Veronika Bachanova
, Ryan D. Cassaday
, Michael Daunov
, Kaitlyn C. Dykes
, Vivian Irizarry Gatell
, Michael R. Grunwald
, Talal Hilal
, La Quisa C. Hill
, Omer Jamy
, Vamsi K. Kota
, Muthu Veera Kumaran
, Chenyu Lin
, Aaron C. Logan
, Marlise R. Luskin

Kristen M. O'Dwyer, Caspian Oliai, Olalekan O. Oluwole, Joshua P. Sasine, Marc S. Schwartz, Melhem M. Solh, Wendy Stock, Stephanie B. Tsai, Mattew Ulrickson, Sumithira Vasu, Eunice S. Wang, Fevzi Firat Yalniz, Stephen A. Strickland, Jessica T. Leonard, Bijal D. Shah, Ibrahim Aldoss

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

Abstract

As highly effective new therapies become widely adopted, issues that are not fully informed by evidence from randomized clinical trials inevitably arise in routine clinical practice. CD19 chimeric antigen receptor T-cell (CAR-T) treatment of adult B-cell lymphoblastic leukemia is a current example where undesirable variation in administration practice is problematic. To fill the gaps and provide a basis for clinical guidance, Muffly and experts from 27 sites followed a modified Delphi method and generated best-practice statements covering patient selection, T-cell collection, bridging, product selection, toxicity mitigation, and longer-term care. Although formulated with US practice in mind, these recommendations are very applicable to CAR-T therapy around the world.

Original language	English (US)
Pages (from-to)	657-668
Number of pages	12
Journal	Blood
Volume	148
Issue number	6
DOIs	https://doi.org/10.1182/blood.2026033559
State	Published - Aug 6 2026

Bibliographical note

Publisher Copyright:
© 2026 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

PubMed: MeSH publication types

Journal Article
Consensus Statement

Publisher link

10.1182/blood.2026033559

Find It

Find It at U of M Libraries

Cite this

Muffly, L., Frey, N. V., Roloff, G. W., Park, J. A., Dholaria, B., Advani, A., Bachanova, V., Cassaday, R. D., Daunov, M., Dykes, K. C., Gatell, V. I., Grunwald, M. R., Hilal, T., Hill, L. Q. C., Jamy, O., Kota, V. K., Kumaran, M. V., Lin, C., Logan, A. C., ... Aldoss, I. (2026). Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood, 148(6), 657-668. https://doi.org/10.1182/blood.2026033559

Muffly, L, Frey, NV, Roloff, GW, Park, JA, Dholaria, B, Advani, A, Bachanova, V, Cassaday, RD, Daunov, M, Dykes, KC, Gatell, VI, Grunwald, MR, Hilal, T, Hill, LQC, Jamy, O, Kota, VK, Kumaran, MV, Lin, C, Logan, AC, Luskin, MR, O'Dwyer, KM, Oliai, C, Oluwole, OO, Sasine, JP, Schwartz, MS, Solh, MM, Stock, W, Tsai, SB, Ulrickson, M, Vasu, S, Wang, ES, Yalniz, FF, Strickland, SA, Leonard, JT, Shah, BD & Aldoss, I 2026, 'Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study', Blood, vol. 148, no. 6, pp. 657-668. https://doi.org/10.1182/blood.2026033559

@article{9b178a35409e49ca98a750235269cbca,

title = "Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study",

abstract = "As highly effective new therapies become widely adopted, issues that are not fully informed by evidence from randomized clinical trials inevitably arise in routine clinical practice. CD19 chimeric antigen receptor T-cell (CAR-T) treatment of adult B-cell lymphoblastic leukemia is a current example where undesirable variation in administration practice is problematic. To fill the gaps and provide a basis for clinical guidance, Muffly and experts from 27 sites followed a modified Delphi method and generated best-practice statements covering patient selection, T-cell collection, bridging, product selection, toxicity mitigation, and longer-term care. Although formulated with US practice in mind, these recommendations are very applicable to CAR-T therapy around the world.",

author = "Lori Muffly and Frey, \{Noelle V.\} and Roloff, \{Gregory W.\} and Park, \{Jae A.\} and Bhagirathbhai Dholaria and Anjali Advani and Veronika Bachanova and Cassaday, \{Ryan D.\} and Michael Daunov and Dykes, \{Kaitlyn C.\} and Gatell, \{Vivian Irizarry\} and Grunwald, \{Michael R.\} and Talal Hilal and Hill, \{La Quisa C.\} and Omer Jamy and Kota, \{Vamsi K.\} and Kumaran, \{Muthu Veera\} and Chenyu Lin and Logan, \{Aaron C.\} and Luskin, \{Marlise R.\} and O'Dwyer, \{Kristen M.\} and Caspian Oliai and Oluwole, \{Olalekan O.\} and Sasine, \{Joshua P.\} and Schwartz, \{Marc S.\} and Solh, \{Melhem M.\} and Wendy Stock and Tsai, \{Stephanie B.\} and Mattew Ulrickson and Sumithira Vasu and Wang, \{Eunice S.\} and Yalniz, \{Fevzi Firat\} and Strickland, \{Stephen A.\} and Leonard, \{Jessica T.\} and Shah, \{Bijal D.\} and Ibrahim Aldoss",

note = "Publisher Copyright: {\textcopyright} 2026 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",

year = "2026",

month = aug,

day = "6",

doi = "10.1182/blood.2026033559",

language = "English (US)",

volume = "148",

pages = "657--668",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia

T2 - a modified Delphi study

AU - Muffly, Lori

AU - Frey, Noelle V.

AU - Roloff, Gregory W.

AU - Park, Jae A.

AU - Dholaria, Bhagirathbhai

AU - Advani, Anjali

AU - Bachanova, Veronika

AU - Cassaday, Ryan D.

AU - Daunov, Michael

AU - Dykes, Kaitlyn C.

AU - Gatell, Vivian Irizarry

AU - Grunwald, Michael R.

AU - Hilal, Talal

AU - Hill, La Quisa C.

AU - Jamy, Omer

AU - Kota, Vamsi K.

AU - Kumaran, Muthu Veera

AU - Lin, Chenyu

AU - Logan, Aaron C.

AU - Luskin, Marlise R.

AU - O'Dwyer, Kristen M.

AU - Oliai, Caspian

AU - Oluwole, Olalekan O.

AU - Sasine, Joshua P.

AU - Schwartz, Marc S.

AU - Solh, Melhem M.

AU - Stock, Wendy

AU - Tsai, Stephanie B.

AU - Ulrickson, Mattew

AU - Vasu, Sumithira

AU - Wang, Eunice S.

AU - Yalniz, Fevzi Firat

AU - Strickland, Stephen A.

AU - Leonard, Jessica T.

AU - Shah, Bijal D.

AU - Aldoss, Ibrahim

PY - 2026/8/6

Y1 - 2026/8/6

N2 - As highly effective new therapies become widely adopted, issues that are not fully informed by evidence from randomized clinical trials inevitably arise in routine clinical practice. CD19 chimeric antigen receptor T-cell (CAR-T) treatment of adult B-cell lymphoblastic leukemia is a current example where undesirable variation in administration practice is problematic. To fill the gaps and provide a basis for clinical guidance, Muffly and experts from 27 sites followed a modified Delphi method and generated best-practice statements covering patient selection, T-cell collection, bridging, product selection, toxicity mitigation, and longer-term care. Although formulated with US practice in mind, these recommendations are very applicable to CAR-T therapy around the world.

AB - As highly effective new therapies become widely adopted, issues that are not fully informed by evidence from randomized clinical trials inevitably arise in routine clinical practice. CD19 chimeric antigen receptor T-cell (CAR-T) treatment of adult B-cell lymphoblastic leukemia is a current example where undesirable variation in administration practice is problematic. To fill the gaps and provide a basis for clinical guidance, Muffly and experts from 27 sites followed a modified Delphi method and generated best-practice statements covering patient selection, T-cell collection, bridging, product selection, toxicity mitigation, and longer-term care. Although formulated with US practice in mind, these recommendations are very applicable to CAR-T therapy around the world.

UR - https://www.scopus.com/pages/publications/105043725488

UR - https://www.scopus.com/pages/publications/105043725488#tab=citedBy

U2 - 10.1182/blood.2026033559

DO - 10.1182/blood.2026033559

M3 - Review article

C2 - 42154904

AN - SCOPUS:105043725488

SN - 0006-4971

VL - 148

SP - 657

EP - 668

JO - Blood

JF - Blood

IS - 6

ER -

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

Abstract

Bibliographical note

UN SDGs

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this